AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29443701
Drug: No polypharmacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No polypharmacy (fewer than 5 unique medications)
Trial: 29443701
Drug: High-risk medications
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk medications
Trial: 29443701
Drug: Prescriptions filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptions filled in the 30 preoperative days
Trial: 29444231
Drug: MOR208, 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOR208, 12 mg/kg intravenously, weekly for 8 weeks, with possible extension based on response.
Trial: 29444644
Drug: Cooper balloon
RxNorm normalized name: COOPER (AS CUPRIC OXIDE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooper balloon catheter (geometric volume of 2.8 ml)
Trial: 29444649
Drug: Therapeutic thoracentesis
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic thoracentesis (withdrawal of pleural fluid in portions of 200 ml up to 1000 ml and 100 ml above 1000 ml)
Trial: 29445030
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg orally daily until disease progression, withdrawal from study, or severe toxicity
Trial: 29445400
Drug: Placebo 3
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 × 1 tablets
Trial: 29445520
Drug: AZL-M 40-mg
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZL-M 40-mg
Trial: 29445520
Drug: AZL-M 80-mg
RxNorm normalized name: M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL-M 80-mg
Trial: 29448849
Drug: Small-molecule immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-molecule immune checkpoint inhibitors of PD-1/PD-L1
Trial: 29448849
Drug: Antibodies binding
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies binding to PD-1 or PD-L1
Trial: 29448936
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) administered by non-rebreather mask for up to 72 hours at 80 ppm
Trial: 29449193
Drug: Intrathecal Mesenchymal
RxNorm normalized name: Bos taurus mesenchyme preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) treatment
Trial: 29450194
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine monitoring and treatment)
Trial: 29451701
Drug: Pasireotide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide (600 μg twice daily), Everolimus (10 mg/day), SIRT (SIR-Spheres dose on days 9 and 37)
Trial: 29452121
Drug: Tofacitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (5 mg b.i.d. initially, escalated to 10 mg b.i.d. for nonresponders)
Trial: 29452209
Drug: Prolactin (PRL)
RxNorm normalized name: prolactin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolactin (PRL) treatment in FFA-induced HepG2 cells
Trial: 29452209
Drug: Prolactin receptor
RxNorm normalized name: Prolactin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolactin receptor (PRLR) overexpression in FFA-induced HepG2 cells
Trial: 29452402
Drug: Mitotane monotherapy
RxNorm normalized name: Mitotane
DrugBank: Mitotane (DB00648)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitotane monotherapy
Trial: 29452421
Drug: LC-MS/MS measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC-MS/MS measurement of cortisol at 30 minutes after intravenous administration of 250 µg tetracosactide acetate.
Trial: 29452421
Drug: LC-MS/MS measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC-MS/MS measurement of cortisol at 60 minutes after intravenous administration of 250 µg tetracosactine acetate.
Trial: 29452421
Drug: LC-MS/MS measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC-MS/MS measurement of 17-OHP at 30 minutes after intravenous administration of 250 µg tetracosactine acetate.
Trial: 29452421
Drug: LC-MS/MS measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC-MS/MS measurement of 17-OHP at 60 minutes after intravenous administration of 250 µg tetracosactine acetate.
Trial: 29452808
Drug: Norepinephrine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine administration during early resuscitation
Trial: 29453190
Drug: Redesigned monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Redesigned monthly emails with content operationalizing anticipated regret, material incentive (behavior), and problem solving.
Trial: 29453305
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose NOACs (1289 patients)
Trial: 29453305
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose NOACs (6636 patients)
Trial: 29454306
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg/d until progression or intolerance
Trial: 29454321
Drug: Temsirolimus, 25
RxNorm normalized name: Temsirolimus, 25 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus, 25 mg IV weekly until progression, unacceptable toxicities or withdrawal
Trial: 29454364
Drug: Oral cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine A at 2.5 mg/kg/day
Trial: 29454660
Drug: CATT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CATT treatment
Trial: 29455032
Drug: Sevoflurane administered
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane administered with an expired fraction target of 2% during short-term procedural sedation.
Trial: 29456529
Drug: High-dose immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose immunosuppressive therapy combined with autologous CD34+ hematopoietic stem cell transplantation (AHSCT)
Trial: 29456629
Drug: Acute vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute vitamin C infusion
Trial: 29457758
Drug: Estradiol transdermal
RxNorm normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal patch (0.3 mg/day) during artificial cycle
Trial: 29457758
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate suppression and estradiol patches
Trial: 29458518
Drug: Daily stress
RxNorm normalized name: Natrol Daily Stress Relief Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily stress in girls
Trial: 29458699
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 2 weeks nightly
Trial: 29459395
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis on the Stroke Emergency Mobile (STEMO)
Trial: 29459395
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis through conventional in-hospital care (CC)
Trial: 29459395
Drug: Both STEMO
RxNorm normalized name: Stemona tuberosa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both STEMO and CC
Trial: 29459949
Drug: Nilotinib during
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib during consolidation phase, followed by treatment discontinuation for TFR.
Trial: 29459949
Drug: Reinitiated nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reinitiated nilotinib therapy after loss of MMR or confirmed loss of MR4 during TFR.
Trial: 29460668
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone in preventing opioid dependence relapse
Trial: 29461859
Drug: Five-Grass Pollen
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-Grass Pollen Tablet Sublingual Immunotherapy
Trial: 29462123
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg every 2 weeks for ≥2 years or until disease progression or unacceptable toxicity
Trial: 29463275
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (PN) initiated within 24 hours of PICU admission
Trial: 29463275
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (PN) withheld for one week in PICU
Trial: 29463490
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing and medication review by a clinical pharmacist, 2 to 5 times over 7 months after standard follow-up at the cardiology clinic.
Trial: 29463490
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing and medication review by a clinical pharmacist.
Trial: 29463550
Drug: Glasdegib in
RxNorm normalized name: Product containing glasdegib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib in combination with standard chemotherapy
Trial: 29464110
Drug: TAK-228 QD
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-228 QD (3 mg)
Trial: 29464110
Drug: TAK-228 3
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-228 3 days/week plus paclitaxel 80 mg/m
Trial: 29464110
Drug: TAK-228 QW
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-228 QW (30 mg)
Trial: 29464110
Drug: TAK-228 (milled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-228 (milled capsules)
Trial: 29466429
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract capsules standardized to 150 mg epigallocatechin-gallate (EGCG) twice a day for 5 days
Trial: 29467098
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tenofovir diphosphate disoproxil fumarate plus emtricitabine provided at no cost
Trial: 29467098
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tenofovir diphosphate disoproxil fumarate plus emtricitabine
Trial: 29467321
Drug: MK-8353 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8353 (400 mg twice daily)
Trial: 29467321
Drug: MK-8353 (100-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8353 (100-800 mg dose cohorts)
Trial: 29467321
Drug: MK-8353 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8353 (various doses)
Trial: 29468069
Drug: Fluid resuscitation
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid resuscitation (≥ 1500 mL)
Trial: 29468069
Drug: Adrenergic agents
RxNorm normalized name: ANTIADRENERGIC AGENTS, CENTRALLY ACTING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenergic agents
Trial: 29468084
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity supervision therapy programme over 12 months
Trial: 29468084
Drug: Moderate intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate intensity supervision therapy programme over 3 months
Trial: 29468173
Drug: High Desipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Desipramine (2-3 mg/kg per day)
Trial: 29468173
Drug: Low Desipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Desipramine (1-2 mg/kg per day)
Trial: 29468455
Drug: Crizotinib 250
RxNorm normalized name: crizotinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib 250 mg BID
Trial: 29468455
Drug: Crizotinib 200
RxNorm normalized name: crizotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib 200 mg BID
Trial: 29468455
Drug: Crizotinib not
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib not exceeding 250 mg daily
Trial: 29470934
Drug: Killed bivalent
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Killed bivalent (O1 and O139) whole-cell oral cholera vaccine (OCV), administered in two doses on day 0 and day 14.
Trial: 29471876
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg twice a day for 3 days
Trial: 29471930
Drug: Compulsory Center-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compulsory Center-Based Treatment (CCT)
Trial: 29472362
Drug: Tadekinig alfa
RxNorm normalized name: Tadekinig alfa
DrugBank: Tadekinig alfa (DB14858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadekinig alfa 80 mg
Trial: 29472362
Drug: Tadekinig alfa
RxNorm normalized name: Tadekinig alfa
DrugBank: Tadekinig alfa (DB14858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadekinig alfa 160 mg
Trial: 29472362
Drug: Tadekinig alfa
RxNorm normalized name: Tadekinig alfa
DrugBank: Tadekinig alfa (DB14858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadekinig alfa (both doses)
Trial: 29474102
Drug: Early palliative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early palliative care visits addressing treatment decisions
Trial: 29474286
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry capsules (implemented in April to September 2016)
Trial: 29474286
Drug: No cranberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cranberry capsules (April to September 2015)
Trial: 29474293
Drug: Pain medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain medication use prior to surgery
Trial: 29474336
Drug: Total endocan
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total endocan levels higher than 4.46 ng/mL
Trial: 29474345
Drug: Morphine titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine titrated in the postanaesthesia care unit (PACU) and patient-controlled intravenous analgesia for 24 hours.
Trial: 29474345
Drug: Morphine-related adverse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-related adverse events observed in patients.
Trial: 29474450
Drug: Native heterodimeric
RxNorm normalized name: Castanea sative leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native heterodimeric IL-15 (hetIL-15) treatment
Trial: 29474565
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy recommendation
Trial: 29475723
Drug: Umbralisib (TGR-1202)
RxNorm normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Umbralisib (TGR-1202) administered orally once per day in 28-day cycles, starting dose of 50 mg, escalating to 1200 mg, with 800 mg of micronised formulation selected as the recommended phase 2 dose.
Trial: 29475762
Drug: rBV A/B
RxNorm normalized name: rBV A/B
DrugBank: Recombinant botulinum A/B vaccine (DB17830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rBV A/B vaccine (0.5 mL, 40-microgram intramuscular injection)
Trial: 29476383
Drug: Linsitinib 150
RxNorm normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linsitinib 150 mg orally twice daily on a 28-day cycle
Trial: 29476660
Drug: Micra leadless
RxNorm normalized name: Lipantil Micro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micra leadless pacemaker implantation and concurrent AVJ ablation
Trial: 29477307
Drug: trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trivalent oral poliovirus vaccine (tOPV)
Trial: 29477307
Drug: tOPV together
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tOPV together with a dose of inactivated poliovirus vaccine (IPV)
Trial: 29477412
Drug: Dextromethorphan 20
RxNorm normalized name: dextromethorphan 20 mg/15 mL oral syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 20 mg / Quinidine 10 mg (DM/Q) twice daily for 90 days
Trial: 29477578
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical activity (DPA) and energy expenditure (EE) assessed over 48 hours using a wearable armband system
Trial: 29477578
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity (IS) measured by euglycaemic insulin clamp
Trial: 29477778
Drug: Carlecortemcel-L (expanded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carlecortemcel-L (expanded cord blood units with cytokines and tetraethylenepentamine)
Trial: 29478026
Drug: Atenolol (β1-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (β1-adrenergic receptor blocker) - monotherapy
Trial: 29478026
Drug: Atenolol (β1-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (β1-adrenergic receptor blocker) - add-on therapy
Trial: 29478343
Drug: Avelumab (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab (human IgG1 monoclonal antibody against PD-L1)
Trial: 29478347
Drug: One-dose MMR
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-dose MMR
Trial: 29480357
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 50 mg/week for 24 weeks followed by ETN for 28 weeks
Trial: 29480357
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO) for 28 weeks after initial treatment with ETN
Trial: 29481737
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept (weight-tiered: 50 mg for 10 to <25 kg, 87.5 mg for 25 to <50 kg, 125 mg for ≥50 kg) administered weekly for 24 months.
Trial: 29481926
Drug: 5,000 units
RxNorm normalized name: Lapase, 1200 units-15,000 units-15,000 units oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 units of unfractionated heparin (UFH)
Trial: 29481970
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vedolizumab and adalimumab
Trial: 29481970
Drug: Current therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current therapies (biologic agents)
Trial: 29483892
Drug: Baseline mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline mean monthly number of attacks
Trial: 29483892
Drug: End of
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End of 3-month diet mean monthly number of attacks
Trial: 29483909
Drug: Autoantibodies (AAb)
RxNorm normalized name: insulin lispro-aabc Cartridge [Lyumjev]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autoantibodies (AAb) against G protein-coupled receptors (GPCRs) in patients with POAG and OHT.
Trial: 29484172
Drug: Apnoeic oxygenation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apnoeic oxygenation (3 l/min oxygen by nasal cannula)
Trial: 29484198
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) program consisting of exercises designed to improve balance and gait, conducted over 8 weeks, twice weekly.
Trial: 29484198
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving the current standard of care following STN-DBS, which does not include prescription of PT.
Trial: 29484198
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) program
Trial: 29484495
Drug: Levodopa alone
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa alone or in combination with a dopamine agonist
Trial: 29484495
Drug: Dopaminergic monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic monotherapy
Trial: 29484495
Drug: Dopamine-substituting therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine-substituting therapies
Trial: 29485066
Drug: Hypofractionated adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated adjuvant whole breast/chest wall and/or regional nodal radiation therapy, 34 Gy in 10 fractions within 2 weeks, followed by a boost of 10 Gy in 5 fractions within 1 week for BCS patients.